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Objectives: Recently, the mitochondrial adenosine triphosphate–sensitive
potassium channel has been suggested to be the final common effector of
myocardial preconditioning. The purpose of this study is to determine
whether selective mitochondrial adenosine triphosphate–sensitive potassium
channel activation alone can precondition human myocardium from an
ischemia/reperfusion insult. 
Methods: Isolated human right atrial trabeculae were placed in tissue baths,
paced, and subjected to 30 minutes of normothermic hypoxia (ischemia) fol-
lowed by 45 minutes of reoxygenation (reperfusion). Trabeculae were pre-
conditioned with a selective mitochondrial adenosine triphosphate–sensitive
potassium channel opener (diazoxide 30 µmol/L) or a nonselective puriner-
gic agonist, adenosine (125 µmol/L), for 5 minutes (adenosine) followed by
a 10-minute washout period. Developed force at end reperfusion (mean ±
standard error) was compared with baseline, and tissue creatine kinase and
adenosine triphosphate levels were measured after ischemia/reperfusion. 
Results: Trabeculae subjected to ischemia/reperfusion exhibited 30% ± 2%
of baseline developed force, whereas trabeculae subjected to selective
adenosine triphosphate–sensitive potassium channel opening (diazoxide)
and nonselective purinergic agonist (adenosine) recovered to 55% ± 7% and
46% ± 3% of baseline developed force, respectively. Tissue creatine kinase
activity was preserved in both the diazoxide- and adenosine-treated trabecu-
lae (5.4 ± 12 and 5.4 ± 14 µmol/L per gram wet tissue) compared with
ischemia/reperfusion (1.8 ± 0.2 U/mg wet tissue). Adenosine triphosphate
levels at end reperfusion were also increased in the trabeculae treated with
selective (diazoxide) and nonselective (adenosine) adenosine triphos-
phate–sensitive potassium channel opener (4.1 ± 0.01 and 4.4 ± 0.2 µmol/L
per gram wet tissue) compared with trabeculae subjected to ischemia/reper-
fusion (1.5 ± 0.1 µmol/L per gram wet tissue).
Conclusions: These results suggest that selective mitochondrial adenosine
triphosphate–sensitive potassium channel activation preconditions human
myocardium and the protection conferred is equal to that of adenosine pre-
conditioning. Targeted openers of mitochondrial adenosine triphosphate–
sensitive potassium channels promote constructive protection of myocellular
energy levels, contractile function, and cellular viability in human myocardi-
um after ischemia/reperfusion. (J Thorac Cardiovasc Surg 2000;120:387-92)
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Transient ischemia before a prolonged ischemicinsult is recognized as providing protection. This
phenomenon is termed ischemic preconditioning.1
Ischemic preconditioning has been demonstrated in
numerous animals,2,3 as well as in human myocardi-
um.4-6 Ischemic preconditioning improves postis-
chemic functional recovery, reduces infarct area,
increases coronary flow, and preserves cellular adeno-
sine triphosphate (ATP) levels.2,7,8 In vivo ischemic
preconditioning in human beings has been reported. In
the Thrombosis in Myocardial Infarction (TIMI) 4
trial, prior angina conferred benefit on in-hospital out-
come during an acute myocardial infarction.9 Attempts
to use transient ischemia as a clinically accessible
means of preconditioning human myocardium have
been limited. Investigational use of ischemic precondi-
tioning, however, has proven protective during coro-
nary artery angioplasty and coronary artery bypass
surgery.10-12 These studies reported a beneficial effect
of ischemic preconditioning according to multiple out-
come criteria. The routine use of ischemic precondi-
tioning during routine coronary artery angioplasty and
coronary bypass surgery has not become standard
among clinicians.
The ATP-sensitive potassium (KATP) channel has
been implicated in both ischemic and purinergic pre-
conditioning of human myocardium.5,13,14 The KATP
channel is present within the plasma, as well as the
mitochondrial membranes. These channels can now be
pharmacologically separated and interrogated with the
use of selective agonists and antagonists. We and oth-
ers5,14-17 have demonstrated that nonselective KATP
channel blockade inhibits both ischemic and purinergic
(adenosine) preconditioning in human myocardium.
The mechanisms involved are not understood because
of the broad effects of these agents. Nonselective KATP
channel activation shortens the action potential, calci-
um currents are affected, and myocardial depression
can occur.18,19 These untoward effects of nonselective
KATP channel activation have prompted interrogation of
targeted mitochondrial KATP channel openers as possi-
ble end effectors of myocardial preconditioning.
Garlid and associates20 reported that diazoxide, a
selective mitochondrial KATP channel opener, precondi-
tioned rat myocardium. Selective mitochondrial KATP
channel blockade abolished the protective effects of
selective mitochondrial KATP channel opening in rat
myocardium. We hypothesized that targeted mitochon-
drial KATP channel activation is sufficient to protect
human myocardium against an ischemia/reperfusion
(I/R) insult through preservation of cellular energy lev-
els, contractile function, and cellular viability.
Materials and methods
Isolated atrial trabeculae. Right atrial trabeculae were
obtained from patients during cannulation for cardiopul-
monary bypass as previously described.14 The study was
approved by the investigational review board of the
University of Colorado Health Sciences Center.
Materials. Modified Tyrode solution was prepared daily
with de-ionized distilled water (ddH2O) and consisted of the
following (in millimoles per liter): D-glucose 5.0; CaCl2 2.0;
NaCl 118.0; KCl 4.0; MgSO4 7H2O 1.2; NaHCO3 25.0; and
NaH2PO4 1.2. All reagents were obtained from Sigma
Chemical Company (St Louis, Mo). The substrate-free
Tyrode solution contained choline chloride (7 mmol/L) to
maintain osmolarity. Diazoxide, a selective mitochondrial
KATP channel opener (Sigma), was dissolved in dimethyl sul-
foxide and then dissolved in Tyrode solution to a final con-
centration of 30 µmol/L in the organ bath. The final concen-
tration of dimethyl sulfoxide was less than 1%. Diazoxide is
a selective KATP channel agonist. Differential effects of diaz-
oxide are concentration dependent. The mitochondrial KATP
channel is 2000 times more sensitive to diazoxide than the
sarcolemmal KATP channel.21 The dose of diazoxide used in
our protocol was determined by a dose-response experiment
(data not shown) and is 1000-fold less than the published
dose for nonselective KATP channel activation. Adenosine, a
nonselective purinergic agonist (Sigma), was dissolved in
deionized water and then dissolved in Tyrode solution to a
final concentration to 125 µmol/L in the organ bath.
Experimental design. Trabeculae were equilibrated for
90 minutes to allow stabilization of developed force.
Trabeculae that failed to generate greater than 250 mg of
developed force were excluded from the study. Pacing was
performed with platinum electrodes (Radnoti Glass, Inc,
Monrovia, Calif) for field stimulation. The electrodes were
placed on either side of the trabeculae and stimulated (Grass
SD9 stimulator; Grass Instruments, Braintree, Mass) with 6-
ms pulses at a voltage 20% above threshold. Contractions
were monitored by force transducers (Grass FT03) and
recorded with a computerized preamplifier and digitizer
(MacLab quad bridge, MacLab/8e, AD Instruments,
Milford, Mass) and continuously monitored with a
Macintosh computer (Apple Computer, Cupertino, Calif).
After equilibration, trabeculae were divided into 4 groups:
(1) control, no ischemia (n = 5); (2) I/R alone without a pre-
conditioning stimulus (n = 6); (3) selective mitochondrial
KATP channel activation (diazoxide) (n = 7); and (4) nonse-
lective purinergic activation (adenosine) (n = 6).
Preconditioned trabeculae were exposed to diazoxide 30
µmol/L or adenosine 125 µmol/L for 5 minutes followed by
a 10-minute washout period, before ischemia.
Groups 2, 3, and 4 were challenged with a 30-minute peri-
od of simulated ischemia, which consisted of substrate-free
hypoxic Tyrode buffer with pacing at 3 Hz, followed by
reperfusion to stable recovery of developed force (45 min-
utes) with normoxic Tyrode solution with pacing at 1 Hz.
Contractile function is reported as developed force in mil-
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ligrams. Developed force is reported as percent change from
baseline.
Preserved trabecular tissue creatine kinase (CK) activ-
ity. End reperfusion tissue creatine kinase (CK) activity was
determined as previously described.2 In brief, trabeculae
were added to 100 volumes of cold isotonic extraction buffer
consisting of imidazole acetate (50 mmol/L), Mg2+ acetate
(10 mmol/L), KH2PO4 (4 mmol/L), ethylenediaminete-
traacetic acid (2 mmol/L), N-acetylcysteine (0.05 mmol/L),
sulfur in 0.8% ethanol (0.0125 mmol/L), and sucrose (250
mmol/L), pH 7.6. Samples were homogenized with a tissue
homogenizer (parallel blades 0.5 cm apart) at half maximal
speed for 20 seconds (10 equally spaced bursts) followed by
centrifugation at 2000g for 5 minutes and 20,000g for 10
minutes. The final supernatant was diluted to less than 0.25
absorbance units per minute. The assay was performed with
Sigma diagnostic kit No. 47-UV on an automated spec-
trophotometer (Hewlett-Packard diode array spectropho-
tometer No. 8452; Hewlett-Packard Company, Andover,
Mass) in cuvettes maintained at 30°C. Samples and reagents
were maintained at 4°C before assay. Results are presented as
units of CK activity per gram wet weight of tissue.
Preserved tissue ATP content. End reperfusion tissue
ATP levels were determined by means of trichloroacetic
acid extraction and a luciferin-luciferase assay. In brief, tra-
beculae were suspended in 500 µL of 10% trichloroacetic
acid and homogenized with a vertishear tissue homogenizer
(parallel blades 0.5 cm apart) at half maximal speed for 20
seconds (10 equally spaced bursts) followed by centrifuga-
tion at 5000g for 10 minutes at 4° C. The supernatant was
decanted and diluted 1:250 with HEPES buffer to a final pH
of 7.75. The assay was performed with the Analytical
Luminescence Laboratory ATP detection kit, catalog No.
5000, on an automated luminometer (Monolight 3010;
Analytical Luminescence Laboratory, San Diego, Calif).22
Samples and reagents were maintained at 4°C before assay.
Results are presented as micromoles per liter per gram wet
weight of tissue.
Statistical analysis. All data are presented as mean ± stan-
dard error. All values were compared by analysis of variance
with application of a post hoc Bonferroni/Dunn test
(StatView 5.0.1, SAS Institute, Inc, Cary, NC).
Results
Eighteen patients were included in this study. The
baseline developed force and trabecular size were sim-
ilar in all groups. Developed force is represented as
percentage of baseline.
No loss in developed force was seen in the trabeculae
treated with selective mitochondrial KATP channel acti-
vation (diazoxide) before the onset of ischemia. This is
in contrast to preconditioning with a nonselective
purinergic agonist (adenosine), where a decrease in
developed force to 55% ± 4% was seen during the pre-
conditioning period and before the ischemic challenge.
After washout of the adenosine, contractile function of
the adenosine-preconditioned trabeculae returned to
99% ± 6% of baseline. Recovery of contractile function
after I/R was increased over I/R alone and was equal to
that of adenosine preconditioning (Fig 1).
Preconditioning with mitochondrial KATP channel open-
ing and nonselective purinergic preconditioning improved
post-I/R developed force compared with I/R alone (Fig 2).
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Fig 1.  Selective (diazoxide) preconditioning did not demon-
strate negative inotropic effects on trabeculae during the 5-
minute treatment period. This is in contrast to the trabeculae
treated with adenosine, which did exhibit a decrease in devel-
oped force (55% of baseline) during the preconditioning period.
I/R, Ischemia/reperfusion; Diaz, diazoxide; CTRL, control.
Fig 2. Selective mitochondrial KATP channel (diazoxide) and
nonselective purinergic preconditioning (adenosine) precon-
ditioning in human atrial trabeculae. Preconditioning with
both diazoxide and adenosine exhibit increased recovery of
developed force relative to untreated trabeculae after
ischemia/reperfusion (I/R). *P < .05 vs I/R alone. Recovery
in the adenosine and diazoxide groups did not return to that
of the control trabeculae. Selective mitochondrial KATP (diaz-
oxide) and purinergic (adenosine) recovery are not different.
Tissue CK activity at end reperfusion was preserved
in both the selective (diazoxide) and purinergic (adeno-
sine) preconditioning trabeculae. The CK activity
remaining after the ischemic challenge in the I/R alone
group was 1.7 ± 0.2 units of activity per gram of wet
tissue weight. This is in contrast to the CK activity pre-
sent in the trabeculae preconditioned with diazoxide
and adenosine, which contained 5.4 ± 14 and 5.4 ± 12
units of CK activity per gram wet myocardium (P < .05
vs I/R alone). CK activity in control trabeculae, per-
fused and paced for the length of the experiment with-
out undergoing I/R, was 7.4 ± 0.25 units per gram wet
tissue (Fig 3).
Cellular energy levels as represented by post-I/R
cellular ATP levels are depicted in Fig 4. The post-I/R
ATP level in trabeculae preconditioned with selective
mitochondrial KATP channel activation (diazoxide)
was 4.1 ± 0.1 µmol/mg wet tissue (P < .05 vs I/R
alone). The ATP level in trabeculae after precondi-
tioning with adenosine was 4.4 ± 0.2 µmol/mg wet
tissue (P < .05 vs I/R alone). The ATP level in tra-
beculae subjected to I/R alone was 1.5 ± 0.1 µmol/mg
wet tissue. The ATP level in trabeculae in the non-
preconditioned, nonischemic control group was 5.1 ±
0.1 µmol/mg wet tissue.
Discussion
The findings of this study are as follows: (1)
Selective mitochondrial KATP channel opening provides
functional protection against a simulated I/R injury; (2)
nonselective purinergic receptor activation before a
simulated I/R injury also provides functional protection
against the I/R injury; (3) post-I/R cellular energy lev-
els are preserved; and (4) selective mitochondrial KATP
channel opening preserves cellular viability after an I/R
injury after preconditioning with selective mitochon-
drial KATP channel activation in human myocardium.
These results demonstrate the ability to selectively pre-
condition human myocardium by directly accessing the
mitochondrial KATP-sensitive channel.
These results provide evidence that the mitochondri-
al KATP channel is an effector of preconditioning in
human myocardium. Previous studies from our labora-
tory have implicated the KATP channel as an end effec-
tor of both purinergic and transient ischemic precondi-
tioning in human myocardium.5,14 No previous reports
in human beings have examined preconditioning stim-
uli specific to the mitochondrial KATP channel. Other
investigators have examined the involvement of the
mitochondrial KATP channel in myocardial precondi-
tioning of various animals/tissues.23,24 Our results sup-
port the observations of Garlid and associates,20 who
first presented the cardioprotective effect of selective
mitochondrial KATP channel openers using reconstitut-
ed heart mitochondria and isolated rat hearts.
In addition to an improvement in postischemic devel-
oped force, we observed an increase in postischemic
cellular ATP levels and tissue CK activity with selec-
tive mitochondrial KATP channel activation (diazoxide).
We postulate that the positive impact on cellular viabil-
ity and cellular energetics is the mechanism by which
direct mitochondrial KATP channel activation protects
human myocardium.
We5,14 and others16,18,24 have previously implicated
the nonselective involvement of the KATP channel in
preconditioning of human myocardium. Recently,
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Fig 3.  Tissue CK activity per gram wet weight of tissue after
reperfusion. Preconditioning with diazoxide and adenosine
preserved tissue CK activity (*P < .05 vs I/R trabeculae), indi-
cating less CK enzyme leak and enhanced tissue viability.
Fig 4. Cellular energy levels after I/R. Selective (diazoxide)
and nonselective purinergic preconditioning increase post-I/R
cellular ATP levels. (*P < .05 vs I/R alone). Preconditioning
with either diazoxide or adenosine did not restore cellular
energy levels to those of untreated control trabeculae.
other investigators have interrogated the selective role
of sarcolemmal as distinct from the mitochondrial
potassium channel. When the plasma membrane KATP
channel is activated, a change in the action potential is
seen that is thought to be due to a change in calcium
handling.25 This altered action potential is not apparent
with activation of the mitochondrial KATP channel. In
our study, no change in the action potential or in the
trabecular contraction profile was seen, implying no
“spillover” involvement of the sarcolemmal KATP chan-
nel with our dose of diazoxide.
Preconditioning with selective mitochondrial KATP
channel opening and with adenosine were both effec-
tive in preserving developed force, cellular viability,
and cellular energy levels. A brief decrease in devel-
oped force was noted with purinergic preconditioning
during the 5-minute treatment period, emphasizing the
advantage of a targeted preconditioning strategy. The
developed force returned to baseline, however, after the
washout of adenosine during the 10 minutes of perfu-
sion before the onset of ischemia. This is in contrast to
selective mitochondrial KATP channel activation, where
there was no loss of developed force during the treat-
ment period. The adenosine-mediated decrease in con-
tractile force observed in our study is consistent with
other studies in which a similar decrease in contractile
force has been described.5,25
Diazoxide is currently in clinical use for noncardio-
protective indications. Diazoxide, a thiazide derivative,
has antihypertensive effects that are profound and have
a rapid onset. Diazoxide also provokes secondary
effects when given at the standard antihypertensive
dose and when given for prolonged periods. These
include hyperglycemia, hirsutism, and water and elec-
trolyte retention. In the present study, no negative
inotropic effects were associated with diazoxide
administration. These side effects should not be clini-
cally observable if diazoxide is used in a single dose for
myocardial preconditioning. A potential concern in
using a direct mitochondrial agent is its ability to pro-
vide comprehensive preconditioning in vivo. It is pos-
sible that by using a receptor-based form of precondi-
tioning, adenosine may more directly activate signaling
pathways within the myocyte. The standard dose of
diazoxide used clinically (17.9 µg/mL) is more than
twice the dose necessary to precondition myocardium
(6.9 µg/mL), emphasizing that clinical use of diazoxide
for myocardial preconditioning should be safe.
Pharmacologic targeting of the mitochondrial KATP
channel may permit constructive cardiac precondition-
ing clinically without the untoward sequelae of nonse-
lective KATP channel activation.
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